Biotech investing is not for impatient investors. So why is it attractive to some investors? Ernest Hemingway penned the line “gradually, then suddenly,” referring to how someone goes bankrupt. But it could also apply to the reason why many investors look for biotech stocks to buy.  The results could take years to prove out, but when they do these stocks can make sharp, outsized moves. And these investors want to make sure they’re in the stock when that spike happens. However, biotech investors aren’t just ...

CAMBRIDGE, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024 at 10:30 a.m. ET in New York. A live webcast will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days follo ...

Beam Therapeutics (BEAM 16.47%) stock thundered out of the gate this week, rising to close nearly 17% higher in price on Monday. Much of this was due to a recommendation upgrade from a prominent bank. By contrast, the S&P 500 only eked out a 0.8% gain.JPMorgan Chase gets more bullish on BeamWell before market open, JPMorgan Chase's (JPM 0.26%) Eric Joseph moved his recommendation on Beam one peg up to overweight (buy, in other words) from the preceding neutral. He also topped off his price target on the bio ...

Key PointsBeam Therapeutics develops precision gene-editing and genetic medication for severe sickle cell disease (SCD).Beam Therapeutics performs a precision form of gene-editing called base-editing using CRISPR/Cas to make a single letter change in the DNA.Prime Medicine pioneered its Prime Editor platform to perform prime-editing, an alternative to CRISPR/Cas9, which allows for the precise replacement of a specific DNA sequence without causing insertion and deletions (indels).5 stocks we like better than ...

The promise of gene editing is moving closer to being a reality. If you’re an investor with a speculative appetite and appropriate risk tolerance, you may want to consider a long position in gene editing stocks. The idea at the core of gene editing is personalized medicine. Tools like 23-and-Me can help you understand your DNA. While knowledge is power, in the case of your personal health, that knowledge has limitations. After all, knowing that you are more genetically predisposed to a certain disease is li ...

Shares of Beam Therapeutics Inc. (BEAM) have rallied 27.3% in the past three months compared with the industry’s increase of 9.8%.Beam’s pipeline of gene editing therapies is based on its proprietary base editing technology. The company is advancing its base editing technology across three disease area portfolios, namely, hematology, immunology/oncology and genetic diseases.The company is developing its leading ex-vivo genome-editing candidate, BEAM-101, for the treatment of sickle cell disease (SCD). The c ...

CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 11:15 a.m. PT in San Francisco. A live webcast will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation. About Beam The ...

Beam Therapeutics Inc. (Exact name of Registrant as specified in its Charter) ☐ Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | --- | --- | --- | |-----------------------------------------|-------------------|-----------------------------------------------------| | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | Common Stock, par value $0.01 per share | BEAM | Nasdaq Global Select Market | This Quarterly Report on Form 10-Q ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------------------|--------|------------|------------|-------|-------|-------|-------|-------|-------|-------|--------------|----------------|----------------------------|-------|-------|----------------------------------------|-------|------------------------| | Commercial | | paper | | | | | | | | $ | Amortized \n | Cost \n578,813 | Gross Unrealized Gains \n$ | 72 | $ | Gross Unrealized Lo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 81-5238376 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 238 Main Street Cambridge, MA 02142 (Address of principal executive of ices) (Zip Code) Registrant's telephone number, including area code: (857) 327-8775 Securities registered pursuant to Section 12(b) of the Act: (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For ...